retatrutide weight loss clinical trial results NEW Phase 3 Review Retatrutide just posted Phase 3

Srenson's thinking was coloured by the fact that a previous drug, Redux, approved in 1996 by the FDA for weight loss and launched with great fanfare, had to be withdrawn a year later after it was found to cause major heart attacks and to be largely ineffective

Tirzepatide is the closest competitor, producing about 25% weight loss over 88 weeks

"These pages are selling a product with no oversight by Medsafe or any regulatory body that ensures the product is safe or effective," Dr Wilde said

They are downstream consequences of these microbiome shifts combined with delayed gastric motility

Oral GLP-1 therapies are frequently associated with gastrointestinal side effects, including nausea, diarrhea, constipation, and vomiting

2 Likes KarlT August 27, 2024, 3:52pm #18 Steve_Combi: With Rt the GCGR enables thermogenisis to increase metabolism